Article Details

Nicolas Girard, MD, on EFS Findings With Nivolumab and Chemotherapy in Resectable NSCLC

Retrieved on: 2022-04-17 14:08:15

Tags for this article:

Click the tags to see associated articles and topics

Nicolas Girard, MD, on EFS Findings With Nivolumab and Chemotherapy in Resectable NSCLC. View article details on hiswai:

Excerpt

Various Monoclonal Antibodies Enhance Durvalumab Efficacy in Resectable, Early-Stage NSCLC · Related Article >>>

Article found on: www.cancernetwork.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up